Hepatoma Research最新文献_第6页

Role of diagnostic radiology in the management of intrahepatic cholangiocarcinoma 诊断放射学在肝内胆管癌治疗中的作用

Hepatoma Research Pub Date : 2023-01-01 DOI: 10.20517/2394-5079.2023.29

Shadi Afyouni, A. Borhani, Alireza Mohseni, M. Mirza-Aghazadeh-Attari, Seyedeh Panid Madani, Haneyeh Shahbazian, Ghazal Zandieh, T. Pawlik, I. Kamel

引用次数: 0

Barriers to surveillance for hepatocellular cancer among patients with chronic liver disease -providers' perspectives 慢性肝病患者肝细胞癌监测的障碍——提供者的观点

Hepatoma Research Pub Date : 2023-01-01 DOI: 10.20517/2394-5079.2023.75

Eliza W. Beal, Leva Gorji, Jaclyn Volney, Lindsey Sova, Ann Scheck McAlearney, Allan Tsung

{"title":"Barriers to surveillance for hepatocellular cancer among patients with chronic liver disease -providers' perspectives","authors":"Eliza W. Beal, Leva Gorji, Jaclyn Volney, Lindsey Sova, Ann Scheck McAlearney, Allan Tsung","doi":"10.20517/2394-5079.2023.75","DOIUrl":"https://doi.org/10.20517/2394-5079.2023.75","url":null,"abstract":"Aims: Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. While patients who are known to be at high risk for HCC should be under surveillance, only 20% of eligible patients in the United States are surveilled. The aim of this study was to identify providers’ perspectives about patient-, provider- and system-level barriers to surveillance for HCC among high-risk patients and to examine provider knowledge and attitudes related to HCC surveillance. We also explored interventions providers suggested as ways to improve HCC surveillance. Methods: Purposive sampling was used to recruit physicians and nurse practitioners in hepatology, gastroenterology, and primary care (internal and family medicine) from one academic medical center to participate in semi-structured interviews. Interviews were transcribed verbatim, and analyzed deductively and inductively to reveal emergent themes. Results: 22 informants were interviewed. During these interviews, several important themes emerged, including: (1) Provider comfort with managing chronic liver disease and the relationships between hepatology, gastroenterology, infectious disease, and primary care providers; (2) Provider knowledge of guidelines for HCC surveillance in high-risk patients and their knowledge about the impact that HCC surveillance can have; (3) How providers discuss HCC surveillance with their high-risk patients; (4) Provider-Level barriers to surveillance; (5) System-level barriers to surveillance; (6) COVID-19; (7) Patient-level barriers to surveillance, and (8) Suggested interventions to improve HCC surveillance rates. Conclusions: In designing interventions to improve HCC surveillance rates of high-risk patients in the United States, there are important targets at the patient, provider and system levels.","PeriodicalId":12959,"journal":{"name":"Hepatoma Research","volume":"22 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135562275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hepatocellular carcinoma in Pacific Islanders: comparison of Pacific Island-born vs. US-born. 太平洋岛民的肝细胞癌：太平洋岛民与美国出生岛民的比较。

Hepatoma Research Pub Date : 2023-01-01 Epub Date: 2023-03-17 DOI: 10.20517/2394-5079.2022.85

Shelby K Yee, Brenda Y Hernandez, Sandi Kwee, Linda L Wong

{"title":"Hepatocellular carcinoma in Pacific Islanders: comparison of Pacific Island-born vs. US-born.","authors":"Shelby K Yee, Brenda Y Hernandez, Sandi Kwee, Linda L Wong","doi":"10.20517/2394-5079.2022.85","DOIUrl":"10.20517/2394-5079.2022.85","url":null,"abstract":"Aim: To describe demographic, clinical, and outcome differences in Pacific Island-born (PI-born) compared to US-born hepatocellular carcinoma (HCC) patients of Pacific Island ancestry within a clinical cohort in Hawaii.Methods: A prospectively collected database of 1608 patients diagnosed with HCC over a 30-year period (1993-2022) identified 252 patients of Pacific Islander ethnicity. Data collected: demographics, medical history, laboratory data, tumor characteristics, treatment, and survival. Patients were divided into two groups: PI-born and US-born. Categorical variables were analyzed using ANOVA and chi-square analysis. Odds ratios with 95% confidence intervals were calculated using univariate and multivariate logistic regression. Overall survival was evaluated using Kaplan-Meier analysis.Results: PI-born patients were younger (57.3 vs. 61.8 years, P = 0.002) and more likely to have hepatitis B (OR 14.10, 7.50-26.50) and underlying cirrhosis (OR 2.28, 1.17-4.45). In comparison, US-born patients had a significantly higher likelihood of Hepatitis C, nonalcoholic steatohepatitis/nonalcoholic fatty liver disease, history of non-HCC cancer, and positive smoking history compared to PI-born patients. PI-born patients were more likely to forego treatment (OR 3.22, 1.77-5.87) and be lost to follow-up (OR 9.21, 1.97-43.03). Both groups were equally likely to have the opportunity for curative surgical treatment (liver resection or transplant). US-born status was associated with higher mortality risk, while transplantation was associated with lower mortality risk. The PI-born cohort demonstrated higher overall survival at 3 and 5 years compared to US-born.Conclusion: HBV remains the primary risk factor for HCC in PI-born patients, whereas HCC in US-born patients is more associated with the adoption of a Westernized lifestyle.","PeriodicalId":12959,"journal":{"name":"Hepatoma Research","volume":"9 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079260/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9708876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Genomic alterations and targeted therapies in extrahepatic cholangiocarcinoma 肝外胆管癌的基因组改变和靶向治疗

Hepatoma Research Pub Date : 2023-01-01 DOI: 10.20517/2394-5079.2023.04

Arnau Oronich, O. Pallisé, A. Salud, R. Montal

{"title":"Genomic alterations and targeted therapies in extrahepatic cholangiocarcinoma","authors":"Arnau Oronich, O. Pallisé, A. Salud, R. Montal","doi":"10.20517/2394-5079.2023.04","DOIUrl":"https://doi.org/10.20517/2394-5079.2023.04","url":null,"abstract":"The global morbimortality of biliary tract cancer (BTC) is steadily increasing and accounts for ~10% of all primary liver cancer. Distinct anatomical locations of BTC have singularities in their etiopathogenesis, which are translated into differences in their molecular fingerprints and the associated therapeutic approaches. Extrahepatic cholangiocarcinoma (eCCA), arising in the large and distal bile ducts, presents recurrent activating mutations of KRAS and loss-of-function alterations in TP53, SMAD4, and CDKN2A/B. Despite being highly prevalent, no targeted therapies are yet available for these oncogenic drivers. ERBB2 mutations and amplifications, on the other hand, are the most recurrent actionable alterations for eCCA, with several clinical trials aiming to provide benefits in biomarker-enriched populations. In addition, integrative multi-omics analysis of eCCA has allowed the identification of novel molecular classes of this disease that could be therapeutically exploited. Beyond that, the highly immunosuppressive tumor microenvironment of eCCA has prevented until now the success of immune checkpoint inhibitors, recently approved in combination with cytotoxic chemotherapy. Further characterization of eCCA at the molecular level would potentially foster treating patients based on a precision oncology approach in order to increase the clinical outcomes for this challenging disease.","PeriodicalId":12959,"journal":{"name":"Hepatoma Research","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67654214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Assessment of response to liver directed radiation-based therapies: Current guidelines, challenges, and future directions 肝定向放射治疗反应评估:当前指南、挑战和未来方向

Hepatoma Research Pub Date : 2023-01-01 DOI: 10.20517/2394-5079.2022.60

Amra Banda, G. Johnson, G. Cunha

{"title":"Assessment of response to liver directed radiation-based therapies: Current guidelines, challenges, and future directions","authors":"Amra Banda, G. Johnson, G. Cunha","doi":"10.20517/2394-5079.2022.60","DOIUrl":"https://doi.org/10.20517/2394-5079.2022.60","url":null,"abstract":"Radiation-based local-regional therapies for hepatocellular carcinoma (HCC) have gained wide acceptance due to promising rates of tumor response, survival, and safety profiles. After treatment, it is important to assess tumor response to determine further management, patient prognosis, and endpoint outcomes for clinical trials. To standardize imaging interpretation and reporting of HCC response to local-regional treatment, a few imaging-based response assessment systems were developed. Two of them have emerged as the most used: the Liver Imaging Reporting and Data System (LI-RADS) Treatment Response Algorithm (LR-TRA) and the modified Response Evaluation Criteria in Solid Tumors (mRECIST). While these systems have been validated for the assessment of response to ablative locoregional therapies, assessment of response to radiation-based therapies can be challenged by persistent or evolving imaging features and is still an area of active research. Following the advances in technology and a better understanding of tumor biology that allowed for the increased application of radiation-based local-regional therapies for the treatment of HCC, research is still needed to address the limitations of current imaging criteria for assessing tumor response to these novel techniques. In this review, we describe radiation-based liver-directed treatment options, examine imaging criteria for assessing treatment response, discuss practical limitations and gaps in knowledge when applying these response criteria, and address future directions that may help to improve accuracy and outcomes when assessing response to radiation-based HCC treatment.","PeriodicalId":12959,"journal":{"name":"Hepatoma Research","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67654413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Improve the precise pathological diagnosis of intrahepatic cholangiocarcinoma: introduction to 2022 expert consensus on pathological diagnosis of intrahepatic cholangiocarcinoma in China 提高肝内胆管癌病理诊断精准度:介绍2022年中国肝内胆管癌病理诊断专家共识

Hepatoma Research Pub Date : 2023-01-01 DOI: 10.20517/2394-5079.2023.11

Xin Zhang

引用次数: 0

Hepatocellular carcinoma after treatment of hepatitis C with direct-acting antivirals: a critical re-appraisal 直接作用抗病毒药物治疗丙型肝炎后的肝细胞癌:一个关键的重新评估

Hepatoma Research Pub Date : 2023-01-01 DOI: 10.20517/2394-5079.2022.35

E. Kouroumalis, Ioannis Tsomidis, A. Voumvouraki

{"title":"Hepatocellular carcinoma after treatment of hepatitis C with direct-acting antivirals: a critical re-appraisal","authors":"E. Kouroumalis, Ioannis Tsomidis, A. Voumvouraki","doi":"10.20517/2394-5079.2022.35","DOIUrl":"https://doi.org/10.20517/2394-5079.2022.35","url":null,"abstract":"Soon after introducing direct-acting antiviral agents (DAAs) for chronic hepatitis C treatment, there began a debate over the possibility of hepatocellular carcinoma (HCC) after viral clearance. Although several reports suggested that the question has been answered negatively, other reports suggested the opposite. The present review presents data in favor and against the null hypothesis and analyzes the scientific background of the possible participation of DAAs in HCC development. The reasons for the discrepancy among studies are presented. These include heterogeneity of patient selection, the nature of the studies, and the tumors themselves are responsible for varying results. Exogenous factors like alcohol consumption or metabolic syndrome confound these findings and suggest the need for statistical adjustments. The need for careful attention to the statistical details is exemplified, and the significant points of almost universal agreements are identified. The conclusion is that the definitive study is impossible for ethical and scientific reasons, and the physician should not ignore even simple personal observations and screening of all patients with extensive fibrosis in HCC, irrespective of sustained virologic response, until a robust, reliable prognostic model can be invented.","PeriodicalId":12959,"journal":{"name":"Hepatoma Research","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67653617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Combined hepatocellular-cholangiocarcinoma: morpho-molecular updates and considerations 合并肝细胞-胆管癌:形态学-分子的更新和考虑

Hepatoma Research Pub Date : 2023-01-01 DOI: 10.20517/2394-5079.2022.81

N. Ahmed, Francesca Falcinelli, M. Rimini, V. Burgio, A. Casadei‐Gardini, L. Aldrighetti, F. Ratti, F. Pedica

引用次数: 0

Mitochondrial calcium signaling in cholangiocarcinoma 胆管癌中的线粒体钙信号传导

Hepatoma Research Pub Date : 2023-01-01 DOI: 10.20517/2394-5079.2023.28

Ana Carolina Loyola-Machado, Mateus T. Guerra, M. Nathanson

引用次数: 0

Risk of hepatocellular carcinoma development in long-term nucles(t)ide analog suppressed patients with chronic hepatitis B 长期核(t)ide类似物抑制的慢性乙型肝炎患者肝细胞癌发展的风险

Hepatoma Research Pub Date : 2023-01-01 DOI: 10.20517/2394-5079.2022.51

M. Fasano, Mariacristina Poliseno, M. Milella, Francesco Rosario Paolo Ieva, M. Ciarallo, B. Caccianotti, T. Santantonio

{"title":"Risk of hepatocellular carcinoma development in long-term nucles(t)ide analog suppressed patients with chronic hepatitis B","authors":"M. Fasano, Mariacristina Poliseno, M. Milella, Francesco Rosario Paolo Ieva, M. Ciarallo, B. Caccianotti, T. Santantonio","doi":"10.20517/2394-5079.2022.51","DOIUrl":"https://doi.org/10.20517/2394-5079.2022.51","url":null,"abstract":"Aim: In long-term nucleos(t)ide analog (NA) suppressed patients with chronic hepatitis B (CHB), hepatocellular carcinoma (HCC) can still develop. Few data exist on the incidence and the predictors of HCC development beyond the first five years in long-term treated patients. To assess the prevalence, incidence, and risk factors for HCC development in a real-life cohort of successfully NA-treated CHB patients for more than five years. Methods: All CHB patients under NAs for ≥ 60 months with stable virologic response were enrolled. HCC surveillance was carried out using liver ultrasound and dosing of serum alpha-fetoprotein every year in patients with CHB and every six months in cirrhotic patients. The baseline PAGE-B score was calculated for each patient. Results: 343 patients (76% male, 86% HBeAg-negative, 30% cirrhotic) were enrolled. During a median (IQR) follow-up of 144 (105-182) months, 21 patients (6%) developed HCC despite virologic suppression (incidence rate 40 cases/1000 person-years follow-up). In multivariate analysis, higher PAGE B score [adjusted Hazard Ratio, aHR 1.26 (95%CI: 1.13-1.54), P = .022] and cirrhosis [aHR 9.71 (95%CI: 2.02-46.48), P = .005] were predictors of HCC development. PAGE B score showed a significant association with HCC (R2 0.225, P < .001) and good prognostic capacity (AUC 0.863) of HCC. Conclusions: Our results confirm that in successfully NA-treated CHB patients, sustained viral replication suppression does not abolish the risk of HCC. The PAGE-B score could be a useful tool for identifying high-risk subjects.","PeriodicalId":12959,"journal":{"name":"Hepatoma Research","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67654324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0